|Dr. Pardeep Nijhawan FRCPC, M.D.||CEO, Company Sec. & Director||165.15k||N/A||1971|
|Dr. Michael J. Brooks M.B.A., Ph.D.||Pres||259.91k||N/A||1978|
|Ms. Kathi Niffenegger CPA, CPA||Chief Financial Officer||143.53k||N/A||1957|
|Mr. Gary Koppenjan||VP of Investor Relations & Communications||N/A||N/A||N/A|
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the development and advancement of treatments for dermatological and gastrointestinal indications. Its lead product candidate is EB01, a non-steroidal anti-inflammatory molecule to treat chronic allergic contact dermatitis. Edesa Biotech, Inc. has a collaborative research project with the National Research Council of Canada to develop novel immunotherapies for vitiligo, as well as other indications; and Light Chain Bioscience for the development and commercialization of two Phase 2-ready biologic drug candidates for various therapeutic, prophylactic, and diagnostic applications. The company was founded in 2015 and is headquartered in Markham, Canada.
Edesa Biotech, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.